$26.80
Manufacturer: Poland
Purpose: Reduces intraocular pressure by inhibiting carbonic anhydrase for glaucoma treatment.
Description
Dorzoptik Combi (dorzolamide) Eye Drops Solution 20 mg/ml. +5 mg/ml. 5 ml. Bottle Dropper №1
Ingredients
Active ingredients: Dorzolamide 20 mg/ml, Timolol 5 mg/ml.
Dosage
Dosage: The usual dose is one drop of Dorzoptik Combi in the affected eye(s) twice daily.
Indications
Indications: Dorzoptik Combi is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Contraindications
Contraindications: Do not use Dorzoptik Combi in patients with bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third-degree atrioventricular block, or overt heart failure.
Directions
Directions: Administer one drop of Dorzoptik Combi in the affected eye(s) twice daily. Do not touch the dropper tip to any surface to avoid contamination.
Scientific Evidence
Dorzoptik Combi combines the carbonic anhydrase inhibitor dorzolamide with the beta-blocker timolol to effectively lower intraocular pressure. Studies have shown that the combination of these two agents provides additive ocular hypotensive effects compared to monotherapy with either component alone.
Additional Information
It is important to inform your healthcare provider about any existing medical conditions or medications before using Dorzoptik Combi. Regular eye examinations are recommended while using this medication to monitor intraocular pressure and assess the progression of glaucoma.
Pharmacological Effects: Dorzoptik Combi works by decreasing the production of aqueous humor in the eye and increasing its outflow, thereby reducing intraocular pressure. Timolol, a beta-blocker, further lowers intraocular pressure by decreasing the production of aqueous humor.
Clinical Trials: Clinical trials have demonstrated the efficacy and safety of Dorzoptik Combi in lowering intraocular pressure in patients with glaucoma or ocular hypertension. A study by Xiong et al. (2018) showed a significant reduction in intraocular pressure with the combination of dorzolamide and timolol compared to dorzolamide alone.
Recent Reviews